Home » Stocks » Exicure

Exicure, Inc. (XCUR)

Stock Price: $2.35 USD -0.03 (-1.05%)
Updated Jul 9, 2020 10:26 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 204.37M
Revenue (ttm) 10.45M
Net Income (ttm) -19.87M
Shares Out 87.15M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 9, 2020
Last Price $2.35
Previous Close $2.37
Change ($) -0.03
Change (%) -1.05%
Day's Open 2.35
Day's Range 2.26 - 2.41
Day's Volume 17,685
52-Week Range 0.96 - 3.84

More Stats

Market Cap 204.37M
Enterprise Value 105.57M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 87.15M
Float 70.12M
EPS (basic) -0.34
EPS (diluted) -0.29
FCF / Share -0.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6,024
Short Ratio 0.02
Short % of Float 0.01%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.55
PB Ratio 2.56
Revenue 10.45M
Operating Income -20.51M
Net Income -19.87M
Free Cash Flow -4.17M
Net Cash 98.80M
Net Cash / Share 1.13
Gross Margin -172.60%
Operating Margin -196.15%
Profit Margin -190.00%
FCF Margin -39.88%
ROA -19.61%
ROE -39.24%
ROIC -75.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(326.44% upside)
Current: 2.35
Target: 10.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth998.31%-98.79%838.13%-
Gross Profit1.300.129.721.04
Operating Income-26.62-21.82-10.41-16.16
Net Income-26.30-22.41-11.01-16.94
Shares Outstanding57.6741.1910.120.11
Earnings Per Share-0.46-0.54-1.09-149.37
Operating Cash Flow1.32-19.49-19.79-5.05
Capital Expenditures-1.08-0.09-0.93-0.39
Free Cash Flow0.24-19.58-20.72-5.44
Cash & Equivalents11126.2725.7619.62
Total Debt4.974.934.865.67
Net Cash / Debt10621.3420.9113.96
Book Value80.7520.9519.982.45
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Exicure, Inc.
Country United States
Employees 43
CEO David A. Giljohann

Stock Information

Ticker Symbol XCUR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XCUR


Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for immuno-oncology, genetic disorders, and other indications. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. Exicure, Inc. has collaboration agreements with Allergan plc; DERMELIX, LLC; and Purdue Pharma L.P. The company was founded in 2011 and is headquartered in Skokie, Illinois.